SOLID TUMORS

This study tests a drug called romiplostim N01 in 60 adults with solid tumors (like lung or breast cancer) who have low platelet counts after radiation combined with other treatments. The goal is to see if the drug safely raises platelet levels within two weeks. It aims to provid…

This study tests special drugs that can both find and treat cancer that has spread to the brain. About 10 adults with advanced breast cancer or other solid tumors will receive a radioactive agent to see if it reaches the brain tumors and helps shrink them. The goal is to measure …

This study tests whether combining lenvatinib (a targeted therapy) with a PD-1 inhibitor (immunotherapy) can shrink or slow advanced solid tumors that have a specific genetic change called 11q13 amplification. About 60 adults with various cancers (like esophageal, head and neck, …

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (including colorectal, stomach, head and neck, and lung cancers) that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main goal is to find the safest dose and check for…

This study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 326 adults aged 18 to 75 with good overall health will take part.

This study tests an experimental drug, BMS-986504, in people with advanced solid tumors that have a missing MTAP gene. The drug is given alone or with other cancer treatments to see if it can shrink tumors and how safe it is. About 260 adults with various cancers (like lung or pa…

This early-phase study tests a new type of cell therapy for people with certain cancers (lymphoma, myeloma, and solid tumors like kidney cancer and sarcoma) that have returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are modified …

This early-phase study tests a new drug, BI 1831169, combined with an existing cancer immunotherapy (anti-PD1 antibody) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find the highest safe dose of BI 183116…

This early-phase study tests a treatment that uses a patient's own immune cells, modified to recognize and attack cancer cells that carry a protein called B7-H3. The study includes up to 40 adults with extensive-stage small cell lung cancer or extrapulmonary neuroendocrine cancer…

This early-stage trial tests the safety of a new drug called ATB-320 in 24 adults with advanced solid tumors that have spread or stopped responding to standard treatments. The main goal is to find the highest safe dose and identify any side effects. Participants will receive the …

This study tests a new radioactive imaging agent called 68Ga-B6FA-01 that targets two different markers on cancer cells and their surroundings. The goal is to see if it can find and stage solid tumors more accurately than current PET scans. About 100 adults with newly diagnosed o…